Research Institute of Influenza, Russia
11
0
0
10
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Moderate Risk
Score: 45/100
0.0%
0 terminated/withdrawn out of 11 trials
100.0%
+13.5% vs industry average
9%
1 trials in Phase 3/4
20%
2 of 10 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (11)
Phase 2 Study of the RSV/Flu-01E Vaccine Against Respiratory Syncytial Virus Infection in Older Adults
Role: lead
Phase 2 Study of the ТВ/Flu-05Е Tuberculosis Vaccine
Role: lead
Reactogenicity, Safety and Immunogenicity of a TB/FLU-04L Tuberculosis Vaccine
Role: collaborator
Safety Trial of Live Attenuated Influenza (H7N3) Vaccine
Role: collaborator
Immunogenicity of H5N1 Vaccine Following H5N2
Role: collaborator
Reactogenicity, Safety and Immunogenicity of a LAIV А/17/Hong Kong/2017/75108 H7N9 Influenza Vaccine
Role: lead
Preventive Effectiveness, Safety and Immunogenicity of a Allantoic Split Inactivated Seasonal Influenza Vaccine
Role: collaborator
Immunogenicity and Safety Study of Allantoic Split Inactivated Seasonal Influenza Vaccine (VSI)
Role: collaborator
Reactogenicity, Safety and Immunogenicity Study of a Allantoic Split Inactivated Seasonal Influenza Vaccine
Role: collaborator
Reactogenicity, Safety and Immunogenicity of a TB/FLU-01L Tuberculosis Vaccine
Role: collaborator
Reactogenicity, Safety and Immunogenicity of a LAIV H7N9 Influenza Vaccine
Role: lead
All 11 trials loaded